1. Vetting the Syrian rebels:
Most of those pushing for providing arms and other aid to the Syrian rebels — which the Obama administration announced last week it will now do — have promised that the rebels could be “vetted” so that weapons and other assistance don’t end up in the hands of jihadists and other bad actors.
I wish I could see a story explaining how that’s going to be done. We seem to have a hard enough time vetting Americans, like Edward Snowden, before giving them top secret security clearances. What’s the plan to separate the good rebels from the bad ones in Syria before letting them lock and load?
2. A gene-screening company’s stock gyrations:
Two weeks ago, I suggested a story about how hedge funds must be using lawyers to handicap an imminent make-or-break Supreme Court decision concerning Myriad Genetics. That’s the company whose claimed patent of a gene has allowed it to charge more than $3,000 for the kind of test used by actress Angelina Jolie to determine whether she was likely to become a breast cancer victim.
Last Thursday at 10:30, the high court issued a unanimous and seemingly dispositive decision — that genes cannot be patented. Yet it seems that there was as much or more speculation and uncertainty after the Court announced its ruling as there was before.
For more than an hour after the decision was handed down — and headlined on most major news websites as a definitive defeat for the gene testing company — Myriad stock was actually up about 8 percent, to an all-time high of $38.27.




